Derivation of midbrain dopaminergic neurons from embryonic stem cells

• US 20030211605A1
• Filed: 04/08/2003
• Published: 11/13/2003
• Est. Priority Date: 05/01/2001
• Status: Abandoned Application

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture, United States As Represented By The Secretary Department of Health and Human Services, United States Department Of Health And Human Services
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Lumelsky, Nadya, Auerbach, Jonathan, Lee, Sang-Hun, Kim, Jong-Hoon, McKay, Ronald D.G., Studer, Lorenz
• Application Number:
  US10/258,975
• Publication Number:
  US 20030211605A1
• Time in Patent Office: Days
• US Class Current: 435/368
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/38 with nuclear receptors
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/58 Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0619 Neurons

Abstract

The invention provides a method of culturing cells. The method generally includes live stages: (1) expansion of ES cells; (2) generation of embryoid bodies; (3) selection of CNS precursor cells; (4) expansion of CNS precursor cells; and (5) differentiation of CNS precursor cells. During the expansion phase, the CNS precursor cells are cultured in a media which includes at least one neurologic agent such as bFGF, SHH, and FGF-8. The expanded CNS precursors are differentiated by withdrawal of at least one neurologic agent, typically, bFGF. Preferably, the differentiation media includes ascorbic acid. The method of the invention can be used to culture a variety of cells, preferably neuronal cells, including, but not limited to dopaminergic neuron cells, cholinergic neuronal cells and serotonergic neuron cells. The invention also provides a method for treating a neurological disorder, such as Parkinson'"'"'s disease, a method of introducing a gene product into a brain of a patient, and an assay for neurologically active substances. The invention further provides a cell culture which includes differentiated neuron cells, of which at least about 20 % of the differentiated neurons are dopaminergic neurons.

Claims

19. A method of culturing dopaminergic neuronal cells, comprising:

a. generating embryoid bodies from the suspension of single embryonic stem cells;

b. selecting central nervous system precursor cells;

c. expanding the central nervous system precursor cells by culturing the central nervous system precursor cells in an expansion medium that comprises at least one neurologic agent and lacks 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid; and

d. differentiating the expanded nervous system precursor cells in an expansion medium that lacks the neurologic agent to form a culture of differentiated neuronal cells that comprises at least about 30% dopaminergic neurons.

1. A method of culturing cells to produce a population of cells comprising neuronal cells, wherein the method comprises:

a. expanding undifferentiated embryonic stem cells in the presence of Leukemia Inhibitory Factor (LIF) and dissociating the undifferentiated embryonic stem cells to form a population comprising a majority of single cells;

b. generating embryoid bodies from the population comprising the majority of single cells;

c. culturing the embryoid bodies to select for central nervous system precursor cells;

d. expanding the central nervous system precursor cells by culturing the central nervous system precursor cells in an expansion medium that comprises at least one neurologic factor and that lacks 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid;

e. differentiating the expanded central nervous system precursor cells to form a culture of differentiated neuronal cells by culturing the expanded central nervous system precursors a culture medium that lacks the neurologic factor,

thereby producing the population of cells comprising ventral neuronal cells.

2. The method of claim 1, wherein the neurologic factor is selected from the group consisting of bFGF, SHH, FGF8, combinations thereof and functional fragments thereof

3. The method of claim 1, wherein the step of differentiating the expanded central nervous system precursor cells to form differentiated neuronal cells comprises culturing the expanded nervous system precursors in a culture medium that lacks bFGF.

4. The method of claim 1, wherein the population of ventral neuronal cells comprises at least about 30% dopaminergic neurons.

5. The method of claim 1, wherein the step of expanding a culture of embryonic stem cells comprises culturing embryonic stem cells for about 4 to about 7 days.

6. The method of claim 1, wherein the embryonic stem cells are human embryonic stem cells.

7. The method of claim 1, wherein the step of expanding a cell culture of embryonic stem cells comprises culturing embryonic stem cells on tissue culture plates.

8. The method of claim 1, wherein the step of expanding a cell culture of embryonic stem cells comprises culturing embryonic stem cells on gelatin coated tissue culture plates.

9. The method of claim 1, wherein the step of generating embryoid bodies comprises culturing expanded embryonic stem cells for about 4 to about 7 days.

10. The method of claim 1, wherein the step of generating embryoid bodies comprises culturing expanded undifferentiated embryonic stem cells in suspension.

11. The method of claim 1, wherein the step of culturing the embryoid bodies to select for central nervous system precursor cells comprises culturing the embryoid bodies in a serum-free medium.

12. The method of claim 1, wherein the step of culturing the embryoid bodies to select for central nervous system precursor cells comprises culturing the embryoid bodies on a fibronectin-coated surface.

13. The method of claim 1, wherein the step of culturing the embryoid bodies to select for central nervous system precursor cells comprises culturing the embryoid bodies for about 6 to about 8 days.

14. The method of claim 1, wherein the step of differentiating the expanded central nervous system precursor cells comprises culturing the expanded central nervous system precursors in a medium which comprises ascorbic acid.

15. The method of claim 1, wherein the population of differentiated neuronal cells comprises dopaminergic neurons.

16. The method of claim 1, wherein the differentiated neuronal cells comprise at least about 30% dopaminergic neurons.

17. The method of claim 1, wherein the differentiated neuronal cells comprise at least about 10% serotonergic cells.

18. The method of claim 1, further comprising a step of transfecting the undifferentiated embryonic stem cells with a gene encoding Nurr1.

20. The method of claim 19, wherein the neurologic agent is selected from the group consisting of basic fibroblast growth factor, sonic hedgehog protein, fibroblast growth factor-8, functional fragments thereof and combinations thereof.

32. The method of claim 31, wherein the culture of differentiated neuronal cells is generated by a method comprising:

a. expanding undifferentiated embryonic stem cells in the presence of Leukemia Inhibitory Factor (LIF) and dissociating the undifferentiated embryonic stem cells to form a population comprising a majority of single cells;

b. generating embryoid bodies from the population comprising the majority of single cells;

c. culturing the embryoid bodies to select for central nervous system precursor cells;

d. expanding the central nervous system precursor cells by culturing the central nervous system precursor cells in an expansion medium that comprises at least one neurologic factor and that lacks 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid;

e. differentiating the expanded central nervous system precursor cells to form a culture of differentiated neuronal cells by culturing the expanded central nervous system precursors in a culture medium that lacks the neurologic factor.

33. The method of claim 32, wherein the step of differentiating the expanded central nervous system precursor cells to form differentiated neuronal cells comprises culturing the expanded central nervous system precursors in a medium which includes ascorbic acid.

44. The method of claim 1, wherein the culture medium is N2 medium.

45. The method of claim 19, wherein the culture medium is N2 medium.

46. The method of claim 1, wherein the expansion media comprises fibroblast growth factor-8 and sonic hedgehog protein.

21. A method of treating a patient with neurological disorder, comprising the steps of:

administering a culture of differentiated neuronal cells to the patient wherein the culture of differentiated neuronal cells comprises at least about 30% dopaminergic neurons.

22. The method according to claim 21 wherein the differentiated neuronal cell culture is derived from embryonic stem cells.

23. The method according to claim 22 wherein the differentiated neuronal cell culture is derived from human embryonic stem cells.

24. The method according to claim 22 wherein the differentiated neuronal cell culture is derived from murine embryonic stem cells.

25. The method according to claim 21, wherein the culture of differentiated neuronal cells is prepared by a method comprising:

a. expanding undifferentiated embryonic stem cells in the presence of Leukemia Inhibitory Factor (LIF) and dissociating the undifferentiated embryonic stem cells to form a population comprising a majority of single cells;

b. generating embryoid bodies from the population comprising the majority of single cells;

c. culturing the embryoid bodies to select for central nervous system precursor cells;

d. expanding the central nervous system precursor cells by culturing the central nervous system precursor cells in an expansion medium that comprises at least one neurologic factor and that lacks 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid;

e. differentiating the expanded central nervous system precursor cells to form a culture of differentiated neuronal cells by culturing the expanded central nervous system precursors in a culture medium that lacks the neurologic factor.

26. The method of claim 25, wherein the method of preparing the culture of differentiated neuronal cells further comprises a step of transfecting the undifferentiated embryonic stem cells with a gene encoding Nurr1.

27. The method of claim 21, wherein the neurological disorder is Parkinson'"'"'s disease.

28. A method of introducing a gene product into a brain of a patient, comprising:

a. transfecting embryonic stem cells;

b. culturing the transfected embryonic stem cells to provide a culture of differentiated neuronal cells comprising at least about 30% dopaminergic neurons; and

c. administering said differentiated transformed neuronal cells into a patient in need thereof.

29. The method of claim 28, wherein the culture of differentiated neuronal cells is generated by a method comprising:

a. expanding undifferentiated embryonic stem cells in the presence of Leukemia Inhibitory Factor (LIF) and dissociating the undifferentiated embryonic stem cells to form a population comprising a majority of single cells;

b. generating embryoid bodies from the population comprising the majority of single cells;

c. culturing the embryoid bodies to select for central nervous system precursor cells;

d. expanding the central nervous system precursor cells by culturing the central nervous system precursor cells in an expansion medium that comprises at least one neurologic factor and that lacks 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid;

e. differentiating the expanded central nervous system precursor cells to form a culture of differentiated neuronal cells by culturing the expanded central nervous system precursors in a culture medium that lacks the neurologic factor.

30. The method of claim 29, wherein said transfected cell produces a gene product selected from the group consisting of tyrosine hydroxylase, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), basic fibroblast growth factor (bFGF), glial derived growth factor (GDNF) NT-3, and NT-4/5.

31. An assay for a substance, comprising:

a. providing a culture of differentiated neuronal cells comprising at least 30% dopaminergic neurons;

b. exposing said differentiated neuronal cells to the substance; and

c. observing the effect of the substance on the differentiated neuronal cells.

34. A cell culture comprising about 50% to about 85% neurons which comprise between about 20% and 40% dopaminergic neurons and between about 1% to about 3% astrocytes.

35. The cell culture of claim 34 wherein the differentiated neuronal cells comprise dopaminergic cells that are functional in vivo.

36. The cell culture of claim 34 wherein at least some of the differentiated neuronal cells are synaptically active.

37. The cell culture of claim 34 wherein the differentiated neuronal cells comprise an exogenous Nurr1 gene.

38. A method of culturing neurons from embryonic stem cells, comprising:

a. expanding undifferentiated the embryonic stem cells on a surface that inhibits differentiation cells in the presence of Leukemia Inhibitory Factor (LIF);

b. disengaging the embryonic stem cells from the surface in clusters;

c. dissociating the clusters of embryonic stem cells to obtain a population which includes a majority of individual cells;

d. generating embryoid bodies in suspension;

e. culturing the embryoid bodies on a coated surface in serum free medium to select for Central Nervous System (CNS) precursor cells;

f. expanding the CNS precursor cells by culturing the cells in an expansion medium that comprises at least one neurologic agent selected from SHH, FGF8, EFG and bFGF; and

g. differentiating the expanded CNS precursor cells to form neurons by withdrawing the at least one neurologic agent from the culture.

39. The method according to claim 38, further comprising adding a differentiation enhancing agent to the culture of central nervous system precursor cells.

40. The method according to claim 39, wherein the differentiation enhancing agent comprises ascorbic acid.

41. The method according to claim 38, wherein the step of culturing the embryoid bodies to select for CNS precursor cells comprises culturing the embryoid bodies in the presence of one or more of differentiation enhancing agents, wherein the differentiation enhancing agent is selenium, insulin, transferrin, or fibronectin.

42. The method of claim 38, further comprises a step of transfecting the undifferentiated embryonic stem cells with a gene encoding Nurr1 prior to the step of expanding the culture of undifferentiated embryonic stem cells.

43. The method of claim 38, wherein the step of expanding the CNS precursor cells comprises culturing the CNS precursor cells in a 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) free medium.

46-1. The method of claim 19, wherein the expansion media comprises fibroblast growth factor-8 and sonic hedgehog protein.